Skip to main content
Open Access Publications from the University of California

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

  • Author(s): Jones, Jeffrey A
  • Hillmen, Peter
  • Coutre, Steven
  • Tam, Constantine
  • Furman, Richard R
  • Barr, Paul M
  • Schuster, Stephen J
  • Kipps, Thomas J
  • Flinn, Ian W
  • Jaeger, Ulrich
  • Burger, Jan A
  • Cheng, Mei
  • Ninomoto, Joi
  • James, Danelle F
  • Byrd, John C
  • O'Brien, Susan M
  • et al.

Published Web Location Commons 'BY' version 4.0 license

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View